ArticleBasic and clinical neuroscience
Effect of Bumetanide on Neural Correlates of Emotion Recognition in Youth With Autism Spectrum Disorder: An Event-related Potential Study.
Article in Basic and clinical neuroscience. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medical treatment of autism spectrum disorder in children: Current evidence, controversies, and clinical challenges.World journal of clinical pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Individuals with autism spectrum disorder (ASD) have impairments in emotion processing, including recognizing facial emotions. There is a significant need for medication to improve core symptoms of ASD. Bumetanide is one of the most recently used drugs in some studies of ASD to address this need. This study aimed to evaluate the effect of bumetanide on the brain response of youth with ASD while they were recognizing facial emotions using the event-related potentials (ERPs). Methods: Fifteen children with ASD aged between 7 to 16 years were evaluated using the childhood autism rating scale (CARS), schedule for affective disorders and schizophrenia for school-age children-present and lifetime version, social responsiveness scale, Wechsler intelligence scale for children-revised form, and standard blood tests. The electrical brain response was measured while they were doing a facial emotion recognition task (FERT). After 3 months of treatment, they were assessed again regarding core symptoms and ERPs. Results: The behavioral problems of the participants decreased significantly based on CARS. With regard to behavioral performance on FERT, the accuracy of detecting emotions increased, and reaction time decreased significantly. The amplitude of N170, EPN, and N250 increased, and latency for N170 and N250 decreased significantly in some electrodes. There were no serious side effects. Conclusion: In this study, bumetanide improved behavioral symptoms and recognition of facial emotions. Also, brain function was improved based on the ERP components. So, bumetanide can be used safely in children and adolescents with ASD to improve the main symptoms of the disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.